Comparisons of Intraocular-Pressure- Lowering Efficacy and Side Effects of 2% Dorzolamide and 1% Brinzolamide
- 20 April 2001
- journal article
- clinical trial
- Published by S. Karger AG in Ophthalmologica
- Vol. 215 (3) , 188-191
- https://doi.org/10.1159/000050856
Abstract
Forty-one healthy volunteers were recruited for a study to compare the intraocular pressure (IOP)-lowering efficacy and side effects of 2% dorzolamide and 1% brinzolamide. In a randomized double-blind design, one eye received one drop of 2% dorzolamide and the other eye received one drop of 1% brinzolamide. The IOP and side effects were evaluated by Goldmann applanation tonometry and slit lamp biomicroscopy before administration, and 3, 7 and 14 days after the initial administration of eyedrops. The IOP decreased significantly from baseline for both drugs (p < 0.05). However, there were no statistically significant differences between 2% dorzolamide and 1% brinzolamide either before or after eyedrop administration (p > 0.05). The most frequent side effect was ocular pain in the case of 2% dorzolamide and blurred vision in 1% brinzolamide. The results suggested that 2% dorzolamide and 1% brinzolamide have similar IOP-lowering efficacies with different side effectsKeywords
This publication has 1 reference indexed in Scilit:
- Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertensionAmerican Journal of Ophthalmology, 1998